Clinical trials sponsored by Chiesi Farmaceutici S.p.A.

Phase breakdown

Conditions studied

Recruiting trials led by Chiesi Farmaceutici S.p.A.

• BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])
  NCT07666490 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists
  NCT07546981 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI)
  NCT05652439 · Phase: Not specified · Ages: 40 Years and older · Sex: All (male and female) · 1 location
• Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
  NCT07301736 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 167 locations

Common questions

How many trials is Chiesi Farmaceutici S.p.A. recruiting for?

Chiesi Farmaceutici S.p.A. is the lead sponsor of 4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.